copper tripeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22CuN6O4 as the complex | Free peptide is C14H24N6O4 |
| Molecular weight | About 402 g/mol | Free peptide is about 340 g/mol |
| Appearance | Blue solid or blue solution | Color from copper d-d transitions |
| Solubility class | Water-soluble; poor in nonpolar solvents | Ionic character favors aqueous media |
| Common synonyms | Copper tripeptide-1; glycyl-L-histidyl-L-lysine copper | INCI listing uses copper tripeptide-1 |
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
The Familia AP (323 in most of the world, GLC for "Great Little Car" in North America) debuted in January 1977 as a rear-wheel-drive subcompact, replacing both the Grand Familia (818) and the preceding Familia (1000/1300). There was a choice of hatchbacks and station wagon bodies, both available with a three- or five-door bodystyle. The station wagon version was a bit later, first being introduced in June 1978, which also meant that the commercial versions based on the 1970 Familia could finally be retired. Three Mazda engines were available, the 985 cc PC, 1,272 cc TC, and the 1415 cc UC (introduced in March 1978). The 1.0-litre unit was only made for export markets. The new Familia shared many parts with the older Mazda Grand Familia. This was the first appearance of the 323 name, for export markets only. The Familia AP was marketed to a new kind of consumer, the Japanese youth, and sold well at home as well as abroad. Nonetheless, the cars traditional rear-wheel-drive underpinnings limited interior space and betrayed themselves in having a very narrow track when compared to the body. The FA4 was somewhat of an interim solution while Mazda worked on a front-wheel-drive car, but still managed to sell around 890,000 examples in its three full years of production. In June 1979, the 323/Familia underwent a facelift, replacing the previous round headlights with rectangular units which were designed as a single unit along with the grille. The new style was in line with that of the recently released Mazda Capella/626 (CB).
Bacterial plasmids are circular sections of DNA that naturally replicate in bacteria. Plasmids are capable of holding inserts up to approximately 20 kbp in length. These types of constructs typically contain a gene offering antibiotic-resistance, an origin of replication, regulatory elements such as Lac inhibitors, a polylinker, and a protein tag which facilitates protein purification. Bacteriophage Vectors are viruses that can infect bacteria and replicate their own DNA. Artificial chromosomes are commonly used in genome project studies due to their ability to hold inserts up to 350 kbp. These vectors are derived from the F plasmid, taking advantage of the high stability and conjugational ability introduced by the F factor. Fosmids are a hybrid between bacterial F plasmids and λ phage cloning techniques. Inserts are pre-packaged into phage particles, then inserted into the host cell with the ability to hold ~45 kbp. They are typically used to generate a DNA library due to their increased stability.
Arizona, 5.53% (187,382 votes) – 11 electoral votes Virginia, 5.78% (260,310 votes) – 13 electoral votes New Jersey, 5.91% (252,498 votes) – 14 electoral votes New Mexico, 6.00% (55,411 votes) – 5 electoral votes Maine, 6.94% (57,514 votes) – 2 electoral votes Maine's 2nd congressional district, 9.03% (33,297 votes) – 1 electoral vote Red denotes states or congressional districts won by Republican Donald Trump; Blue denotes those won by Democrat Kamala Harris.
=== EC 1.8.5 With a quinone or similar compound as acceptor === EC 1.8.5.1: glutathione dehydrogenase (ascorbate) EC 1.8.5.2: thiosulfate dehydrogenase (quinone) EC 1.8.5.3: respiratory dimethylsulfoxide reductase EC 1.8.5.4: bacterial sulfide:quinone reductase EC 1.8.5.5: thiosulfate reductase (quinone) EC 1.8.5.6: sulfite dehydrogenase (quinone) EC 1.8.5.7: glutathionyl-hydroquinone reductase EC 1.8.5.8: eukaryotic sulfide quinone oxidoreductase EC 1.8.5.9: protein dithiol:quinone oxidoreductase DsbB EC 1.8.5.10: DsrC-trisulfide reductase
Sources: en.wikipedia.org
Similar to urine testing, a drawback of using 1H MRS as a test for CTD is that the results of the test could be attributed to any of the cerebral creatine deficiencies. The most accurate and reliable method of testing for CTD is through DNA sequence analysis of SLC6A8. DNA analysis of SLC6A8 allows the identification of the location and type of variant causing the cerebral creatine deficiency. Furthermore, DNA analysis of SLC6A8 is able to prove that a cerebral creatine deficiency is due to CTD and not GAMT or AGAT deficiency.
In early April, Sykes and Picot were appointed to act as the chief negotiators once more, this time on a month-long mission to the Middle East for further discussions with the Sherif of Mecca and other Arab leaders. On 3 April 1917, Sykes met with Lloyd George, Lord Curzon and Maurice Hankey to receive his instructions in this regard, namely to keep the French onside while "not prejudicing the Zionist movement and the possibility of its development under British auspices, [and not] enter into any political pledges to the Arabs, and particularly none in regard to Palestine". Before travelling to the Middle East, Picot, via Sykes, invited Nahum Sokolow to Paris to educate the French government on Zionism. Sykes, who had prepared the way in correspondence with Picot, arrived a few days after Sokolow; in the meantime, Sokolow had met Picot and other French officials, and convinced the French Foreign Office to accept for study a statement of Zionist aims "in regard to facilities of colonization, communal autonomy, rights of language and establishment of a Jewish chartered company." Sykes went on ahead to Italy and had meetings with the British ambassador and British Vatican representative to prepare the way for Sokolow once again. Sokolow was granted an audience with Pope Benedict XV on 6 May 1917. Sokolow's notes of the meeting – the only meeting records known to historians – stated that the Pope expressed general sympathy and support for the Zionist project.
Cupping (拔罐; báguàn) is a type of Chinese massage, consisting of placing several glass "cups" (open spheres) on the body. A match is lit and placed inside the cup and then removed before placing the cup against the skin. As the air in the cup is heated, it expands, and after placing in the skin, cools, creating lower pressure inside the cup that allows the cup to stick to the skin via suction. When combined with massage oil, the cups can be slid around the back, offering "reverse-pressure massage".
The Gent hyperelastic material model is a phenomenological model of rubber elasticity that is based on the concept of limiting chain extensibility. In this model, the strain energy density function is designed such that it has a singularity when the first invariant of the left Cauchy-Green deformation tensor reaches a limiting value
=== Techdirt === In January 2017, Ayyadurai, again represented by Harder, filed a $15 million libel lawsuit on similar grounds against Techdirt founder Mike Masnick and two other parties for a series of articles published beginning in September 2014. In February, Masnick, represented by the firm Prince Lobel, filed two motions to dismiss. One motion argued that the articles were constitutionally protected opinion and written about a public figure without actual malice. The second motion asked for dismissal under California's anti-SLAPP law that compensates defendants for some legal expenses. In September 2017, United States District Judge F. Dennis Saylor dismissed the defamation claims against Techdirt, but declined to strike the complaint under the anti-SLAPP law. In his ruling, Saylor wrote that definitions of "email" vary widely. Therefore, "whether plaintiff's claim to have invented e-mail is 'fake' depends upon the operative definition of 'e-mail.' Because the definition does not have a single, objectively correct answer, the claim is incapable of being proved true or false." The two parties filed cross-appeals with the U.S. Court of Appeals for the First Circuit but settled out of court in May 2019, with each side agreeing to pay their own legal costs and Techdirt's articles to remain online with an added link to a rebuttal on Ayyadurai's website.
Sources: en.wikipedia.org
Early devices typically delivered low amounts of nicotine than that of traditional cigarettes, but newer devices containing a high amount of nicotine in the liquid may deliver nicotine at amounts similar to that of traditional cigarettes. Similar to traditional cigarettes, e-cigarettes rapidly delivers nicotine to the brain. The peak concentration of nicotine delivered by e-cigarettes is comparable to that of traditional cigarettes. E-cigarettes take longer to reach peak concentration than with traditional cigarettes, but they provide nicotine to the blood quicker than nicotine inhalers. The yield of nicotine users obtain is similar to that of nicotine inhalers. Newer e-cigarette models deliver nicotine to the blood quicker than with older devices. E-cigarettes with more powerful batteries can delivery a higher level of nicotine in the e-cigarette vapor. Some research indicates that experienced e-cigarette users can obtain nicotine levels similar to that of smoking. Some vapers can obtain nicotine levels comparable to smoking, and this ability generally improves with experience. E‐cigarettes users still may be able to obtain similar blood nicotine levels compared with traditional cigarettes, particularly with experienced smokers, but it takes more time to obtain such levels.
== History == The first to write about MG were Thomas Willis, Samuel Wilks, Erb, and Goldflam. The term "myasthenia gravis pseudo-paralytica" was proposed in 1895 by Jolly, a German physician. Mary Walker treated a person with MG with physostigmine in 1934. Simpson and Nastuck detailed the autoimmune nature of the condition. In 1973, Patrick and Lindstrom used rabbits to show that immunization with purified muscle-like acetylcholine receptors caused the development of MG-like symptoms.
The judiciary of the EU has played an important role in the development of EU law. It interprets the treaties, and has accelerated economic and political integration. Today the Court of Justice of the European Union (CJEU) is the main judicial body, within which there is a higher Court of Justice that deals with cases that contain more public importance, and a General Court that deals with issues of detail but without general importance, and then a separate Court of Auditors. Under the Treaty on European Union article 19(2) there is one judge from each member state in the Court of Justice and General Court (27 on each at present). Judges should "possess the qualifications required for appointment to the highest judicial offices" (or for the General Court, the "ability required for appointment to high judicial office"). A president is elected by the judges for three years. While TEU article 19(3) says the Court of Justice is the ultimate court to interpret questions of EU law, in practice, most EU law is applied by member state courts (e.g. the German Bundesgerichtshof, the Belgian Cour du travail, and formerly the English Court of Appeal). Member state courts can refer questions to the CJEU for a preliminary ruling. The CJEU's duty is to "ensure that in the interpretation and application of the Treaties the law is observed", although realistically it has the ability to expand and develop the law according to the principles it develops consistently with democratic values.
In stage 1, creatinine and SDMA values are still within the normal range. However, there are other disorders of kidney function, such as an inadequate ability to concentrate, protein loss via the urine, morphological kidney changes or an increase in the values on repeated measurements. Creatinine and SDMA values often indicate a different stage. This may be due to the biological fluctuation range, concomitant diseases, influencing factors outside the kidney and pre-analytical causes. In this case, staging should be based on the higher value and the determination should be repeated after two to four weeks.
=== Phase 2 === ASP-8062 – GABAB receptor positive allosteric modulator – alcoholism BP-1.3656B (BP-1.3656; BP1.3656B; BP13656) – histamine H3 receptor antagonist – alcoholism BP-1.4979 (BP-1.4979; BP-14979; BP14979) – dopamine D3 receptor partial agonist – smoking withdrawal Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – smoking withdrawal Buprenorphine sublingual ethanol-free (CHF-6563; CHF6563) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone (naloxone/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Bupropion/dextromethorphan (bupropion/DXM; Auvelity; AXS-05) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist, CYP2D6 inhibitor) and dextromethorphan (DXM) (NMDA receptor antagonist, serotonin reuptake inhibitor, sigma receptor agonist, other actions) – smoking withdrawal Bupropion/naltrexone (Contrave; CX-101; Mysimba; naltrexone/bupropion; NB32) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist) and naltrexone (opioid receptor antagonist) – smoking withdrawal Cannabidiol (CBD; A-1002-N5S; Nantheia) – cannabinoid/various actions – opioid-related disorders, smoking withdrawal Cannabidiol (CBD; Epidiolex; Epidyolex; Epidiolexa; GW-42003; GWP-42003; GWP-42003-P; JZP-926) – cannabinoid/various actions – heroin-related disorders, opioid-related disorders Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – smoking withdrawal Cocaine esterase (RBP-8000; TNX-1300) – enzyme replacement – cocaine-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – alcoholism Devextinetug (anti-methamphetamine chimeric monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb) – immunomodulator (monocloncal antibody against methamphetamine) – substance-related disorders F-652 (IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; rhIL-22 dimer) – interleukin, immunoglobulin Fc fragment, recombinant fusion protein, anti-inflammatory, hepatoprotectant – alcoholism and alcoholic hepatitis Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor, toll-like receptor 4 (TLR4) antagonist – alcoholism, opioid-related disorders, substance-related disorders Liraglutide (LATIN-T1D; NN-2211; NN-9211; NN-8022; NNC-90-1170; Saxenda; Victoza) – glucagon-like peptide-1 (GLP-1) receptor agonist – smoking withdrawal Lixosicone (AEF-0117; AEF0117) – biased cannabinoid CB1 receptor negative allosteric modulator (pregnenolone derivative) – substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – alcoholism Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist – alcoholism Mebufotenin benzoate (5-MeO-DMT; BPL-002; BPL-003) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – cocaine-related disorders Midomafetamine (MDMA) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, entactogen – alcoholism Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – alcoholism Miricorilant (CORT-118335) – glucocorticoid and mineralocorticoid receptor antagonist – alcoholism Nadolol (INV-102; INV102) – non-selective beta blocker (β1- and β2 adrenergic receptor agonist) – smoking withdrawal Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate glycine-gated NMDA receptor agonist – cocaine-related disorders NNC0194-0499 (NN-9500; NN-9499; NNC-0194-0499) – fibroblast growth factor (FGF) receptor agonist – substance-related disorders NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – cocaine-related disorders OMS-405 (OMS405) – PPARγ agonist – opioid-related disorders, smoking withdrawal Pemvidutide (ALT-801- Altimmune; SP-1373; VPD-107) – glucagon-like peptide-1 (GLP-1) receptor agonists, glucagon receptor agonist – alcoholism Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Selonabant (ANEB-001; V-24343) – cannabinoid CB1 receptor antagonist – substance-related disorders Sunobinop (IMB-115; IT-1315; RSC117957; S-117957; V-117957) – nociceptin receptor agonist – alcoholism TA-CD (TA-CD; TA-CD09) – immunostimulant (cocaine vaccine) – cocaine-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – alcoholism Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – opioid-related disorders
Sources: en.wikipedia.org
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.
Copper(II) complexes absorb light in the red part of the visible spectrum, so transmitted light appears blue. The absorption arises from electronic transitions within the copper d-orbitals, which are split by the surrounding ligands. The intensity and exact wavelength shift somewhat with pH, solvent, and ligand arrangement.
The free peptide and the copper-bound complex are studied as separate species and do not always behave the same way in assays. Some reported responses are attributed to copper delivery, while others are attributed to the peptide sequence itself. Which fraction drives a given observation is often unresolved in the published work.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).